SynthesisEuropean journal of drug metabolism and pharmacokinetics2026
Clinical Relevance of the 516 G>T Polymorphism in CYP2B6 and Its Effects on Efavirenz Concentrations in Patients with HIV and Tuberculosis: A Meta-analysis.
Synthesis in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveEfavirenz is associated with frequent adverse effects, mainly hepatotoxicity and central nervous system disturbances. The cytochrome P450 enzyme CYP2B6 plays a key role in efavirenz metabolism and is strongly linked to these toxicities. This study aimed to evaluate the effect of the CYP2B6 c.516 G>T polymorphism on efavirenz plasma concentrations by comparing individuals with GG, GT, and TT genotypes.
methodsA systematic review of four databases was conducted to identify studies published up to March 2025 evaluating the association between the CYP2B6 c.516 G>T polymorphism and efavirenz plasma concentrations. Pooled mean differences with 95% confidence intervals were calculated using random-effects models.
resultsFive studies, including 373 patients, met the inclusion criteria. Individuals with the TT genotype showed significantly higher plasma efavirenz concentrations compared with GG and GT carriers. The mean differences in plasma concentration between the GT-TT and GG-TT subgroups were 5.65 µg/mL and 6.41 µg/mL, respectively, both statistically significant (p < 0.05). No significant difference was observed between the GG and GT genotypes.
conclusionThis meta-analysis confirms that the CYP2B6 c.516 TT genotype is significantly associated with elevated plasma efavirenz concentration in patients with HIV and tuberculosis. While higher concentrations may increase toxicity risk, this was not directly evaluated in the current pooled analysis. These findings support the potential utility of pharmacogenetic testing to optimize efavirenz dosing and minimize the risk of adverse effects, particularly in carriers of the TT genotype. The observed heterogeneity among studies may be attributed to ethnic variability and differences in sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.